Syndax Pharmaceuticals (NASDAQ:SNDX) Upgraded to Hold at StockNews.com

StockNews.com upgraded shares of Syndax Pharmaceuticals (NASDAQ:SNDX) from a sell rating to a hold rating in a research note published on Friday morning.

Other equities analysts have also recently issued reports about the stock. JPMorgan Chase & Co. lowered their price target on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. The Goldman Sachs Group raised their price target on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. HC Wainwright lifted their price target on Syndax Pharmaceuticals from $47.00 to $49.00 and gave the company a “buy” rating in a report on Tuesday, November 12th. Bank of America increased their price objective on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. Finally, Barclays boosted their target price on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an “overweight” rating in a research report on Thursday, August 15th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $36.18.

Syndax Pharmaceuticals Stock Up 1.8 %

Shares of Syndax Pharmaceuticals stock opened at $16.11 on Friday. Syndax Pharmaceuticals has a 12 month low of $14.97 and a 12 month high of $25.34. The stock has a market cap of $1.38 billion, a PE ratio of -4.44 and a beta of 0.92. The business has a fifty day simple moving average of $18.87 and a 200-day simple moving average of $20.19.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.13) by $0.15. The business had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $9.16 million. During the same period last year, the firm earned ($0.73) EPS. Analysts expect that Syndax Pharmaceuticals will post -3.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SNDX. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter worth approximately $27,000. Values First Advisors Inc. acquired a new stake in Syndax Pharmaceuticals during the third quarter worth $30,000. nVerses Capital LLC bought a new stake in Syndax Pharmaceuticals in the 2nd quarter valued at $33,000. Quantbot Technologies LP bought a new stake in Syndax Pharmaceuticals in the 3rd quarter valued at $49,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after buying an additional 541 shares in the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).